Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28789582 | 0.98 | PDE10A (0.56) | PDE10ASMN1; SMN2LMNAKDM4ETP53 | |
| Hydrochloric Acid SCHEMBL2953393 | 0.98 | PDE10A (0.56) | PDE10ASMN1; SMN2LMNAKDM4ETP53 | |
| SCHEMBL3192555 | 0.90 | ALDH1A1 (0.52) | SMN1; SMN2LMNAKDM4EHSP90AA1MAPT | |
| SCHEMBL2036823 | 0.85 | MCHR1 (0.57) | PDE10ASMN1; SMN2HSP90AA1MAPTALOX15 | |
| SCHEMBL18221300 | 0.85 | PDE5A (0.49) | PDE10ASMN1; SMN2LMNAKDM4ETP53 | |
| SCHEMBL8544603 | 0.82 | PDE10A (0.57) | PDE10ASMN1; SMN2LMNAKDM4ETP53 | |
| SCHEMBL12853992 | 0.81 | LMNA (0.64) | PDE10ASMN1; SMN2LMNAKDM4ETP53 | |
| SCHEMBL14900783 | 0.81 | LMNA (0.64) | PDE10ASMN1; SMN2LMNAKDM4ETP53 | |
| SCHEMBL19630330 | 0.81 | HSP90AA1 (0.52) | PDE10ASMN1; SMN2HSP90AA1MAPTALOX15 | |
| SCHEMBL28290618 | 0.81 | PDE10A (0.45) | PDE10ASMN1; SMN2LMNAKDM4EHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111217840-B | Linear phenanthroline copper complex and preparation method and application thereof | 浙江工业大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-111100124-B | Linear o-phenanthroline compound and preparation method and application thereof | 浙江工业大学 | 2021-12-07 | — | — | CN | disclosed |
| CN-111217840-A | Linear phenanthroline copper complex and preparation method and application thereof | 浙江工业大学 | 2020-06-02 | — | — | CN | disclosed |
| CN-111100124-A | Linear o-phenanthroline compound and preparation method and application thereof | 浙江工业大学 | 2020-05-05 | — | — | CN | disclosed |
| CN-106986870-B | Organic electric field color changing device and o-diazaphenanthrene based compound used for the same | 机光科技股份有限公司 | 2019-07-12 | — | — | CN | disclosed |
| US-9831444-B1 | Phenanthroline-based compound for organic electroluminescence device | UDC IRELAND LIMITED (IE) | 2017-11-28 | — | — | US | disclosed |
| US-9831444-B1 | Phenanthroline-based compound for organic electroluminescence device | UDC IRELAND LIMITED (IE) | 2017-11-28 | — | — | US | disclosed |
| US-9831444-B1 | Phenanthroline-based compound for organic electroluminescence device | UDC IRELAND LIMITED (IE) | 2017-11-28 | — | — | US | disclosed |
| CN-106986870-A | Organic electric field color changing device and o-diazaphenanthrene based compound used for the same | 机光科技股份有限公司 | 2017-07-28 | — | — | CN | disclosed |
| EP-2232612-B1 | OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS | GLOBAL OLED TECHNOLOGY LLC (US) | 2017-02-08 | — | — | EP | disclosed |
| US-8956738-B2 | Organic element for low voltage electroluminescent devices | GLOBAL OLED TECHNOLOGY LLC (US) | 2015-02-17 | — | — | US | disclosed |
| US-8900722-B2 | OLED device employing alkali metal cluster compounds | GLOBAL OLED TECHNOLOGY LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-8900722-B2 | OLED device employing alkali metal cluster compounds | GLOBAL OLED TECHNOLOGY LLC (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2485892-A1 | ORGANIC ELEMENT FOR LOW VOLTAGE ELECTROLUMINESCENT DEVICES | Global OLED Technology LLC (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044009-A1 | ORGANIC ELEMENT FOR LOW VOLTAGE ELECTROLUMINESCENT DEVICES | GLOBAL OLED TECHNOLOGY LLC (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20100019671-A1 | ORGANIC ELEMENT FOR LOW VOLTAGE ELECTROLUMINESCENT DEVICES | EASTMAN KODAK COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-20090142618-A1 | OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS | GLOBAL OLED TECHNOLOGY LLC | 2009-06-04 | — | — | US | disclosed |
| US-20090142618-A1 | OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS | GLOBAL OLED TECHNOLOGY LLC | 2009-06-04 | — | — | US | disclosed |
| WO-2009054905-A1 | OLED DEVICE WITH FLUORANTHENE ELECTRON TRANSPORT MATERIALS | EASTMAN KODAK COMPANY (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142618-A1 | OLED DEVICE EMPLOYING ALKALI METAL CLUSTER COMPOUNDS | OCIAD2, OCIAD1, OSTC | PDE10A 4870/4885SMN1; SMN2 4517/4885LMNA 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.